Reports Q2 -$0.30 v -$0.27e, R$12.1M v $14.0Me
- CEO: We are also focused on initiating a new randomized dose-ranging trial for Iclusig aimed at further improving the benefit/risk profile of this approved medicine and accelerating patient enrollment in the ALTA clinical trial of AP26113 in patients with ALK-positive non-small cell lung cancer.